Kura Oncology Inc at Barclays Global Healthcare Conference Transcript
Hello again, everyone. My name is Etzer Darout, senior biotech analyst at Barclays. It's my pleasure to welcome Kura Oncology to our next fireside chat. With me this morning, I have Troy Wilson, President and Chief Executive Officer, and Brian Powl, Chief Commercial Officer.
Maybe just to get us started, Troy, if maybe you can just make some introductory remarks for the team, and then we'll go into a Q&A.
Yeah. Yeah, thanks, Etzer. Thank you to you and Barclays for inviting us to attend the conference. It's always terrific.
So as folks probably know, Kura is now a commercial stage, fully integrated, biopharma focused on developing targeted therapies for both liquid tumors and solid tumors. We have sort of three priorities this year that we're going to -- I'm sure we're going to talk about in your Q&A.
But the first is to drive the launch of our marketed product, KOMZIFTI, to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
